The financing “provides Neuros with capital to complete enrollment” of the QUEST (High-FreQUEncy Nerve Block for PoST-Amputation Pain) study, and to submit an anticipated application for pre-market approval, the company said in the release. It described QUEST as “a 180-subject, randomized, double blinded, active sham controlled clinical trial that is being conducted under an Investigational Device Exemption,” or IDE, and is designed to assess the safety and effectiveness of the company’s Altius High-Frequency Nerve Block system to treat intractable post-amputation pain.
Click here to read the complete story.
Story excerpt provided by Crain’s Cleveland Business.
Written by Scott Suttell.
Originally published January 7, 2021.